BioPharma Resources

Drug Trial Radar · NCT07522151

Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer

A Randomized, Double-blind, Multicenter Phase III Trial of Adebrelimab (SHR-1316) Plus S-1 and Oxaliplatin (SOX) Versus Placebo Plus S-1 and Oxaliplatin in the Perioperative Treatment of Resectable Gastric or Gastroesophageal Junction Cancer

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 874 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

874

Planned (sponsor's estimate)

Start

May 7, 2026

Primary completion

Dec 2029

Study completion Feb 2034

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate the efficacy, safety and tolerability of the two combination regimens.

Conditions

  • Locally Advanced Gastric or Gastroesophageal Junction Cancer

Interventions

  • Adebrelimab plus S-1 and oxaliplatinDrug

    Adebrelimab plus S-1 and oxaliplatin

  • Adebrelimab blank preparation plus S-1 and oxaliplatin.Drug

    Adebrelimab blank preparation plus S-1 and oxaliplatin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator-assessed EFSTime frame: About 8 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.